Keros Therapeutics, Inc. (KROS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Keros Therapeutics reported revenue of $243.9M, up 6769.4% from $3.5M the year before. Net income was $87.0M (a 35.7% net margin), or $2.30 per diluted share. Operating margin was 27.7%. Operating activities generated $107.5M of cash, leaving $106.0M of free cash flow. At fiscal year end, Keros Therapeutics held $338.0M in total assets against $34.9M in total liabilities, including $287.4M of cash and equivalents.
Open the full interactive Keros Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Keros Therapeutics Key Stats
| Share Price | $11.23 |
|---|---|
| Market Cap | $222.4M |
| P/E Ratio | 4.9 |
| 52-Week Range | $9.91 – $21.84 |
| Shares Outstanding | 19.8 million (basic, 2026 Q2) |
Keros Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $20.1M | $0 | $151,000 | $3.5M | $243.9M |
| Operating Income | -$46.7M | -$56.4M | -$114.8M | -$169.9M | -$210.8M | $67.6M |
| Pre-Tax Income | -$45.5M | -$56.7M | -$104.7M | -$153.0M | -$187.1M | $91.9M |
| Income Tax | -$172,000 | $2.0M | $0 | $0 | $300,000 | $4.9M |
| Net Income | -$45.4M | -$58.7M | -$104.7M | -$153.0M | -$187.4M | $87.0M |
| Diluted EPS | -$2.93 | -$2.52 | -$4.15 | -$5.20 | -$5.00 | $2.30 |
Keros Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $14.1M | $380,000 | $32,000 | $0 |
| Net Income | -$7.3M | -$23.5M | -$23.7M | -$28.7M |
| Diluted EPS | -$0.18 | -$0.62 | -$1.21 | -$1.45 |
Keros Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $265.9M | $230.0M | $279.0M | $331.1M | $559.9M | $287.4M |
| Current Assets | $267.7M | $251.4M | $285.8M | $347.3M | $588.9M | $315.4M |
| Total Assets | $269.4M | $255.3M | $306.8M | $370.0M | $615.9M | $338.0M |
| Current Liabilities | $7.2M | $11.8M | $16.5M | $24.4M | $27.4M | $20.4M |
| Total Liabilities | $7.7M | $12.1M | $29.4M | $37.8M | $44.3M | $34.9M |
| Shareholders' Equity | $261.7M | $243.2M | $277.4M | $332.2M | $571.6M | $303.1M |
Keros Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$36.9M | -$62.1M | -$70.1M | -$124.5M | -$160.9M | $107.5M |
| Cash From Investing | -$294,000 | -$1.0M | -$1.2M | -$2.5M | -$1.9M | -$1.6M |
| Cash From Financing | $296.0M | $28.6M | $120.3M | $179.0M | $391.8M | -$378.5M |
| Free Cash Flow | -$37.2M | -$63.2M | -$71.3M | -$127.0M | -$162.8M | $106.0M |
Figures from Keros Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Keros Therapeutics financials page for every line item.
Keros Therapeutics Company Profile
| Ticker | KROS |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Lexington, Massachusetts |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001664710 |
Frequently Asked Questions
What was Keros Therapeutics' revenue in fiscal 2025?
Keros Therapeutics (KROS) reported revenue of $243.9M for fiscal 2025.
What is Keros Therapeutics' annual revenue history?
Keros Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $20.1M; 2022: $0; 2023: $151,000; 2024: $3.5M; 2025: $243.9M.
What was Keros Therapeutics' net income in fiscal 2025?
Keros Therapeutics reported net income of $87.0M for fiscal 2025.
What was Keros Therapeutics' earnings per share (EPS) in fiscal 2025?
Keros Therapeutics' diluted EPS was $2.30 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Keros Therapeutics generate in fiscal 2025?
Keros Therapeutics generated $106.0M of free cash flow in fiscal 2025.
What was Keros Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Keros Therapeutics reported revenue of $0.
How many shares of Keros Therapeutics are outstanding?
Keros Therapeutics reported a weighted average of 19.8 million basic shares outstanding in 2026 Q2.
What is Keros Therapeutics' market cap?
Based on its latest closing price, Keros Therapeutics (KROS) has a market capitalization of about $222.4M.
When does Keros Therapeutics' fiscal year end?
Keros Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Keros Therapeutics headquartered?
Keros Therapeutics lists its business address in Lexington, Massachusetts in its SEC filings.